紫杉类联合蒽环类方案新辅助化疗在乳腺癌治疗中的近期疗效观察  

Short term efficacy of paclitaxel combined with anthracycline neoadjuvant chemotherapy in treatment of breast cancer

作　　者：石秀换[1] 刘明法[2] 

机构地区：[1]内蒙古医科大学附属医院保健中心,呼和浩特010050 [2]呼和浩特市第一医院急诊科

出　　处：《中国医药》2015年第3期386-389,共4页China Medicine

摘　　要：目的观察紫杉类联合蒽环类（TE）方案新辅助化疗在乳腺癌治疗中的近期疗效。方法选取2011年3月至2013年3月内蒙古医科大学附属医院收治的100例接受新辅助化疗的乳腺癌患者，依据随机数字表法分为观察组和对照组，每组50例。观察组患者第1天静脉滴注紫杉醇175mg／m^2或多西紫杉醇75mg／m^2，静脉注射表阿霉素70mg／m^2，同时服用地塞米松预处理，3周为1个疗程；对照组患者给予静脉注射环磷酰胺第1天500mg／m^2＋表阿霉素第1天70mg／m^2＋氟尿嘧啶第1天、第8天500mg／m^2，3周为1个疗程。治疗3个疗程后，观察2组患者的治疗有效率及不良反应发生情况。结果观察组50例患者中完全缓解13例，部分缓解28例，总有效率为82．0％；对照组50例患者中完全缓解10例，部分缓解21例，总有效率为62．0％。观察组患者总有效率明显高于对照组，差异有统计学意义（P〈0．05）；观察组患者Ⅱb期、Ⅲa期、Ⅲb期缓解率分别为80．0％（8／10）、81．8％（18／22）、83．3％（15／18），均明显高于对照组的61．5％（8／13）、60．0％（12／20）、58．8％（10／17），差异有统计学意义（均P〈0．05）；观察组患者的不良反应发生率为10．O％（5／50）明显低于对照组的22．0％（11／50），差异有统计学意义（P〈0．05）。结论TE方案新辅助化疗在乳腺癌治疗中的应用效果良好。Objective To observe the short-term efficacy of paclitaxel combined with anthracycline （TE） neoadjuvant chemotherapy in treatment of breast cancer. Methods The clinical data of 100 breast cancer patients receiving neoadjuvant chemotherapy from March 2011 to March 2013 in the Affiliated Hospital of Inner Mongolia Medical University were retrospectively analyzed. According to the random number table, the patients were randomly divided into observation group （50 cases） receiving intravenous infusion of paclitaxel （ 175 mg/m^2） or docetaxel （75 mg/m^2 ） plus epirubicin （70 mg/m^2） on the first day after pretreatment with dexamethasone; control group received intravenous injection of cyclophosphamide （500 mg/m^2 ） plus epirubicin （70 mg/m^2 ） plus fluorouracil （500 mg/m^2 ） on the first day and the eighth day. Each course of treatment consisted of 3 weeks. The size of primary tumor and situation of axillary lymph nodes were observed and compared between the two groups. Results There were 13 cases of complete remission and 28 cases of partial remission in observation group, with total treatment effective rate of 82.0% （41/50）. There were 10 cases of complete remission and 21 cases of partial remission, with total treatment effective rate of 62.0% （31/50）. The total treatment effective rate of observation group was significantly higher that of control group （ P 〈 0.05 ）. The remission rates of observation group in IIb stage, m a stage, m b stage were significantly higher than those of control group[80.0% （8/10） vs 61.5% （8/13）,81.8% （18/22） vs 60.0% （12/ 20） ,83.3% （15/18） vs 58.8% （10/17） ] （P 〈 0.05）. The adverse reaction rate of observation group [ 10.0% （5/50）1 was significantly lower than that of control group [ 22. 0% （11/50）, P 〈 0. 05 ]. Conclusion The effect of TE neoadjuvant chemotherapy is good in treatment of breast cancer.

关 键 词：TE方案新辅助化疗 乳腺癌 治疗 应用 

分 类 号：R737[医药卫生—肿瘤]